Axsome Therapeutics, Inc. (NASDAQ:AXSM) today announced that the U.S. Food and Drug Administration (FDA) has approved AUVELITYTM (dextromethorphan HBr -bupropion HCl) extended-release tablets for the treatment of major depressive disorder (MDD) in adults.1 AUVELITY is the first and only rapid-acting oral medicine approved for the treatment of MDD with labeling of statistically significant antidepressant efficacy compared to placebo starting at one week.1-4 The rapid antidepressant effects of AUVELITY were sustained at all subsequent timepoints.1 AUVELITY is the first and only oral N-methyl D-aspartate (NMDA) receptor antagonist approved for the treatment of MDD.3 Axsome anticipates AUVELITY to be commercially available in the U.S. in the fourth quarter of 2022.
Trump-Linked SPAC Digital World’s Stock Is Volatile After 2024 Presidential Campaign Launch: What’s Up?
Digital World Acquisition Corp (NASDAQ: DWAC) gapped down over 6% on Thursday, in tandem with the general market, which saw the SPDR S&P 500 start the trading session 1.34% below Wednesday’s closing price after
